PolyPeptide Group AG
SIX:PPGN
Intrinsic Value
PolyPeptide Group AG is a contract development and manufacturing organization for clinical and approved commercial-stage peptide drug substances used in peptide-based therapeutics. [ Read More ]
The intrinsic value of one
PPGN
stock under the Base Case scenario is
23.91
CHF.
Compared to the current market price of 33.55 CHF,
PolyPeptide Group AG
is
Overvalued by 29%.
PolyPeptide Group AG's market capitalization is 1.1B CHF.
PPGN stock price is 33.55 CHF.
PPGN stock (23.91 CHF) is 29% less than its price (33.55 CHF).
PPGN has downside potential of 22% compared to the average analyst price target.
Open Wall St Estimates
PPGN's Revenue has grown by 15% over the past 12 months.
PPGN has positive Gross Profit for the last twelve months.
PPGN has negative Operating Income for the last twelve months.
PPGN's Revenue is forecast to grow at a rate of 17% per year over the next 3 years.
PPGN has negative Net Income for the last twelve months.
PPGN has negative Net Debt. This means that the company has more cash and short-term investments (96m EUR) than debt (78m EUR).
PPGN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -6%.
PPGN has a very low three-year average ROIC (Return on Invested Capital): 2%. The company is not efficient at using invested capital to generate operating income.
PPGN's short-term assets (327m EUR) exceed its short-term liabilties (176m EUR).
PPGN's ROE (Return on Equity) for the past 12 months is negative and is equal to -13%.
PPGN has negative three-year average ROE (Return on Equity): 0%. The company is not efficient at transforming stockholders' equity into net income.
PPGN's Altman Z-Score is equal to 1.87.
PPGN's long-term assets (689m EUR) exceed its long-term liabilties (308m EUR).
PPGN has negative Free Cash Flow for the last twelve months.
PPGN's D/E (Debt to Equity) is very low and is equal to 0.2.
PPGN doesn't generate enough operating income (-34m EUR) to safely cover interest payments on its debt (5m EUR).
Valuation Backtest
PolyPeptide Group AG
Run backtest to discover the historical profit from buying and selling
PPGN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
PolyPeptide Group AG
Balance Sheet Decomposition
PolyPeptide Group AG
| Current Assets | 326.6m |
| Cash & Short-Term Investments | 95.7m |
| Receivables | 86.2m |
| Other Current Assets | 144.7m |
| Non-Current Assets | 362.5m |
| Long-Term Investments | 5.2m |
| PP&E | 324.1m |
| Intangibles | 16.5m |
| Other Non-Current Assets | 16.7m |
| Current Liabilities | 176.5m |
| Accounts Payable | 60.9m |
| Other Current Liabilities | 115.5m |
| Non-Current Liabilities | 131.4m |
| Long-Term Debt | 77.8m |
| Other Non-Current Liabilities | 53.6m |
Earnings Waterfall
PolyPeptide Group AG
|
Revenue
|
324.9m
EUR
|
|
Cost of Revenue
|
-315.6m
EUR
|
|
Gross Profit
|
9.3m
EUR
|
|
Operating Expenses
|
-43m
EUR
|
|
Operating Income
|
-33.7m
EUR
|
|
Other Expenses
|
-17.7m
EUR
|
|
Net Income
|
-51.4m
EUR
|
Free Cash Flow Analysis
PolyPeptide Group AG
PPGN Profitability Score
Profitability Due Diligence
PolyPeptide Group AG's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
PolyPeptide Group AG's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
PPGN Solvency Score
Solvency Due Diligence
PolyPeptide Group AG's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
PolyPeptide Group AG's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PPGN Price Targets Summary
PolyPeptide Group AG
According to Wall Street analysts, the average 1-year price target for
PPGN
is 26 CHF
with a low forecast of 19.19 CHF and a high forecast of 32.52 CHF.
Shareholder Return
PPGN Price
PolyPeptide Group AG
| Average Annual Return | 15.41% |
| Standard Deviation of Annual Returns | 134.42% |
| Max Drawdown | -90% |
| Market Capitalization | 1.1B CHF |
| Shares Outstanding | 32 987 924 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
PolyPeptide Group AG
Country
Industry
Market Cap
Dividend Yield
Description
PolyPeptide Group AG is a contract development and manufacturing organization for clinical and approved commercial-stage peptide drug substances used in peptide-based therapeutics. The company is headquartered in Zug, Zug and currently employs 1,041 full-time employees. The company went IPO on 2021-04-29.
Contact
IPO
Employees
Officers
The intrinsic value of one
PPGN
stock under the Base Case scenario is
23.91
CHF.
Compared to the current market price of 33.55 CHF,
PolyPeptide Group AG
is
Overvalued by 29%.
You don't have any saved screeners yet
